SINGLE AGENT DOCETAXEL AS SECOND- LINE CHEMOTHERAPY FOR PRETREATED PATIENTS WITH RECURRENT NON- SMALL CELL LUNG CANCER

Journal Title: Journal of IMAB - Annual Proceeding (Scientific Papers) - Year 2013, Vol 19, Issue 1

Abstract

 Objective: Single agent Docetaxel is a standard therapy for patients with non- small cell lung cancer after the failure of platinum- containing regimens. The aim of this study was to explore the efficacy and safety of Docetaxel monotherapy as second- line chemotherapy in pretreated patient with inoperable non- small cell lung cancer. Methods: From January 2005 to May 2008 thirty- six consecutive patients with locally advanced or metastatic morphologically proven stage IIIB/ IV non- small cell lung cancer entered the study after failure of previous platinum- based regimens. Treatment schedule consist of Docetaxel 75 mg/m2 administered every three weeks with repetition after 21 days with Dexamethasone premedication. Results: Overall response rate, median time to progression and median survival was 16,6 %, 4,5 months and 5,6 months respectively. The main hematological toxicity was neutropenia. Conclusions: That data suggest that single agent Docetaxel remain reasonable choices for the chemotherapy in pretreated patients with non- small cell lung cancer.

Authors and Affiliations

Deyan Davidov

Keywords

Related Articles

DYNAMIC SPREAD OF BRUCELLOSIS IN HUMANS IN THE AREA OF KORCA FOR THE YEARS 1999-2009

Brucellosis disease is progressing rapidly, marking not only the vast spread to cattle, but now seriously endangering human health. Brucellosis is an infectious disease dekurs chronic, caused by bacteria of the genus Bru...

COMPARISON OF THE TIME REQUIRED FOR ULTRASONIC REMOVAL OF PREFABRICATED INTRARADICULAR POSTS.

Aim: To measure in vitro and compare the time necessary for ultrasonic removal of different prefabricated stainless steel and fiber posts, cemented with one and the same resin cement. Methodology: Thirty extracted human...

 BEVACIZUMAB COMBINED WITH IRINOTECAN, 5-FLUOROURACIL AND LEUCOVORIN AS THE FIRST- LINE TREATMENT IN PATIENTS WITH METASTATIC COLORECTAL CARCINOMA

 Objective: Bevacizumab improved survival when added to chemotherapy for patients with metastatic colorectal cancer (mCRC). The aim of this study was to explore the efficacy and safety of Bevacizumab containing chem...

THE DYNAMICS OF ANTIMICROBIAL RESISTANCE OF Salmonella typhimurium ISOLATES

Salmonella typhimurium is the most common pathogen isolated in foodstuffs toxin infections. The development of antibiotic resistance in Salmonella typhimurium over the last twenty years is caused by an extensive applicat...

SOCIAL COMPETENCE IN 18-YEARS-OLD STUDENTS WHO HAD PERFORMED AN AGGRESSIVE ACT AT SCHOOL

The social competence as a general concept, consist of social, emotional, cognitive and behavioral skills. It is regarded as a basic quality of effectiveness at social interactions associated with successful behavioral p...

Download PDF file
  • EP ID EP146701
  • DOI 10.5272/jimab.2013191.387
  • Views 79
  • Downloads 0

How To Cite

Deyan Davidov (2013).  SINGLE AGENT DOCETAXEL AS SECOND- LINE CHEMOTHERAPY FOR PRETREATED PATIENTS WITH RECURRENT NON- SMALL CELL LUNG CANCER. Journal of IMAB - Annual Proceeding (Scientific Papers), 19(1), 387-390. https://europub.co.uk/articles/-A-146701